search
Back to results

IN Sub-Dissociative Ketamine vs IN Fentanyl

Primary Purpose

Bone Fracture

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
ketamine
fentanyl
ibuprofen or acetaminophen
Sponsored by
Wake Forest University Health Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Bone Fracture

Eligibility Criteria

4 Years - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • single suspected, isolated extremity fracture that requires analgesia

Exclusion Criteria:

  • GCS < 15 at ED presentation,
  • reported allergy or adverse reaction to ketamine or fentanyl,
  • pregnancy,
  • intoxication,
  • hypotension (less than 70 mmHg +2x age or less than 90 mm Hg for patients greater than 11 years of age)
  • weight > 70 kg
  • patients receiving opioid analgesia administered prior to arrival
  • multiply injured patients (injuries to multiple extremities)
  • aberrant nasal anatomy that precludes IN medications

Sites / Locations

  • Carolinas Medical Center Main - Levine Children's Hospital Emergency Department

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

ketamine

fentanyl

Arm Description

ketamine (1mg/kg)

fentanyl (1.5 micrograms/kg)

Outcomes

Primary Outcome Measures

Primary Outcome: Number of Participants With Minor Side Effects and Significant Adverse Events
We will conclude that such a study is NOT feasible if we observe a rate of side effects for ketamine that exceeds fentanyl by three-fold or event rate of 5% or more for ketamine-related significant adverse events. Side effects are common events experienced by patients receiving ketamine or fentanyl that do not change outcomes for the patient but may affect the patient experience. A significant adverse event (SAE) includes any adverse event that begins after the short form consent has been completed that causes a threat to life, limb or an organ system, causes prolongation of hospitalization, or requires new medical or surgical treatment to correct.

Secondary Outcome Measures

Secondary Outcome: Total Dose of Opioid Pain Medication in Morphine Equivalents/kg/Hour
Compare the total dose of opioid pain medication in morphine equivalents/kg/hour required during the ED evaluation of children with suspected forearm fractures after randomization and treatment with IN ketamine or IN fentanyl.

Full Information

First Posted
August 5, 2015
Last Updated
June 30, 2022
Sponsor
Wake Forest University Health Sciences
Collaborators
Carolinas Trauma Network Research Group, Charlotte, Houston, Milwaukee Prehospital Emergency Research Nodal Center-CHaMP-ERNC
search

1. Study Identification

Unique Protocol Identification Number
NCT02521415
Brief Title
IN Sub-Dissociative Ketamine vs IN Fentanyl
Official Title
Randomized Controlled Trial of Intranasal Ketamine Compared to Intranasal Fentanyl for Analgesia in Children With Suspected, Isolated Extremity Fractures in the Pediatric Emergency Department
Study Type
Interventional

2. Study Status

Record Verification Date
February 2018
Overall Recruitment Status
Completed
Study Start Date
December 2015 (undefined)
Primary Completion Date
November 2016 (Actual)
Study Completion Date
November 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Wake Forest University Health Sciences
Collaborators
Carolinas Trauma Network Research Group, Charlotte, Houston, Milwaukee Prehospital Emergency Research Nodal Center-CHaMP-ERNC

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This single center, randomized control, double blind trial will prospectively examine the feasibility of intranasal, sub-dissociative (IN) ketamine versus intranasal fentanyl for pain control in the pediatric emergency department setting. The investigators hypothesize that IN ketamine may provide a safe and effective alternative to IN fentanyl for children with suspected, isolated extremity fractures. Eighty children ages 3-17 years with a suspected, isolated extremity fracture that requires analgesia will be randomized to receive IN ketamine or IN fentanyl upon presentation to the emergency department and will be followed for 2 hours for efficacy and 6 hours for safety.
Detailed Description
Intranasal medications are commonly used in place of parenteral opioids in children. IN fentanyl is the most commonly used intranasal analgesic medication in the pediatric population with demonstrated safety and efficacy comparable to IV fentanyl and IV morphine. IN ketamine, at sub-dissociative doses, offers similar safety and efficacy to IN fentanyl and the additional advantage of potentially reducing the total use of opioid agents during the emergency department visit. Ketamine is easily stored and has a wide therapeutic window with an extremely low risk of cardiorespiratory complications. This study will compare the safety and efficacy of IN ketamine to IN fentanyl in children with suspected, isolated extremity fractures in the pediatric emergency department. The primary aim of the study is to examine the feasibility of future protocol expansion. The investigators will conclude that additional studies are NOT feasible if the observed rate of side effects for ketamine that exceeds fentanyl by three-fold or event rate of 5% or more for ketamine-related SAEs. The primary aim of the study will compare the frequency of adverse events over 6-hours among children randomized to receive either intranasal sub-dissociative ketamine (IN ketamine) or intranasal fentanyl (IN fentanyl) for pain control in the emergency department. The exploratory aim of the study will compare the efficacy of intranasal ketamine to intranasal fentanyl as measured by a reduction in age appropriate pain scale scores over 2-hours. The secondary aim of the study will compare the total dose of opioid pain medication in morphine equivalents/kg/hour required during the ED evaluation of children with suspected, isolated extremity fractures after randomization and treatment with IN ketamine or IN fentanyl. Eighty children ages 3-17 years with a suspected, isolated extremity fracture that requires analgesia will be randomized to receive IN ketamine or IN fentanyl upon presentation to the emergency department and will be followed for 2 hours for efficacy and 6 hours for safety. All participants will be premedicated with acetaminophen or ibuprofen and baseline data, including pain level, will be collected. The trial consists of two treatment arms. (IN ketamine 1 mg/kg or IN fentanyl 1.5 mcg/kg). Randomization will follow a 1:1 ratio, with approximately 40 per group. Randomization will be stratified by ages 3-10 and 11-17. The participants will be assessed by a research coordinator for adverse events every 5 minutes using an adverse events checklist for the first fifteen minutes post study medication administration and every 30 minutes for the first two hours after drug administration. The vital signs and pain scale assessment will be repeated every 10 minutes for the first 30 minutes and then every 30 minutes for the first two hours after drug administration. A final assessment will be made 6 hours after the last dose of study drug or at discharge from the ED to assess for late side effects or adverse events. Study medication may be repeated times one at a reduced dose after 20 minutes when the full effects of the first dose are known. The decision to administer additional study medication (0.5 mg/kg ketamine or 0.75 mcg/kg fentanyl ) will at be at the discretion of the treating physician. Should a second dose of study medication be required, a new schedule of patient assessments will commence following the same schedule as for the first dose. Participant assessments will continue until the 2 hour endpoint is reached from the time of the last drug administration, with a final assessment at 6 hours after the last dose of study drug or at discharge from the ED to assess for late side effects or adverse events.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bone Fracture

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
87 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ketamine
Arm Type
Experimental
Arm Description
ketamine (1mg/kg)
Arm Title
fentanyl
Arm Type
Active Comparator
Arm Description
fentanyl (1.5 micrograms/kg)
Intervention Type
Drug
Intervention Name(s)
ketamine
Other Intervention Name(s)
intranasal pain medication
Intervention Description
intranasal (IN) sub-dissociative ketamine (1mg/kg)
Intervention Type
Drug
Intervention Name(s)
fentanyl
Other Intervention Name(s)
intranasal pain medication
Intervention Description
Intranasal (IN) fentanyl (1.5 micrograms/kg)
Intervention Type
Drug
Intervention Name(s)
ibuprofen or acetaminophen
Intervention Description
10 mg/kg of ibuprofen or 15 mg/kg of acetaminophen will be given to participants prior to the randomized intervention
Primary Outcome Measure Information:
Title
Primary Outcome: Number of Participants With Minor Side Effects and Significant Adverse Events
Description
We will conclude that such a study is NOT feasible if we observe a rate of side effects for ketamine that exceeds fentanyl by three-fold or event rate of 5% or more for ketamine-related significant adverse events. Side effects are common events experienced by patients receiving ketamine or fentanyl that do not change outcomes for the patient but may affect the patient experience. A significant adverse event (SAE) includes any adverse event that begins after the short form consent has been completed that causes a threat to life, limb or an organ system, causes prolongation of hospitalization, or requires new medical or surgical treatment to correct.
Time Frame
60 minutes
Secondary Outcome Measure Information:
Title
Secondary Outcome: Total Dose of Opioid Pain Medication in Morphine Equivalents/kg/Hour
Description
Compare the total dose of opioid pain medication in morphine equivalents/kg/hour required during the ED evaluation of children with suspected forearm fractures after randomization and treatment with IN ketamine or IN fentanyl.
Time Frame
participants will be followed during the emergency department length of stay, estimated to average 6 hours
Other Pre-specified Outcome Measures:
Title
Exploratory Outcome: Reduction in Age Appropriate Pain Scale Scores
Description
Mean difference in the reduction of the pain scale scores at 20 minutes. Two commonly used, age appropriate and previously validated, pediatric pain assessment tools were used: FACES Pain Scale - Revised for children ages 4-10 and the Visual Analog Scale for children ages 11-17. The FACES Pain Scale - Revised is a self-reported measure of pain intensity developed for children with pain intensity represented by images of grimacing faces on a scale of 0 (no pain) to 10 (maximum pain). The Visual Analog Scale is a self-reported measure of pain intensity where patients mark their pain level on a 10 cm line that represents a continuum of no pain at 0 cm and worst pain at 10 cm. For analysis, pain scale data were merged and reported as values form 0 to 100. The minimum clinically significant reduction in pain was defined as a decrease of 20.
Time Frame
20 minutes
Title
Secondary Safety Outcome: Adverse Events Over 6 Hours
Description
Compare the frequency of types of adverse events over 6-hours among children randomized to receive either intranasal sub-dissociative ketamine (IN ketamine) or intranasal fentanyl (IN fentanyl) for pain control in the emergency department.
Time Frame
6 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
4 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: single suspected, isolated extremity fracture that requires analgesia Exclusion Criteria: GCS < 15 at ED presentation, reported allergy or adverse reaction to ketamine or fentanyl, pregnancy, intoxication, hypotension (less than 70 mmHg +2x age or less than 90 mm Hg for patients greater than 11 years of age) weight > 70 kg patients receiving opioid analgesia administered prior to arrival multiply injured patients (injuries to multiple extremities) aberrant nasal anatomy that precludes IN medications
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stacy Reynolds, MD
Organizational Affiliation
Carolinas Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Carolinas Medical Center Main - Levine Children's Hospital Emergency Department
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28203
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
27609854
Citation
Reynolds SL, Studnek JR, Bryant K, VanderHave K, Grossman E, Moore CG, Young J, Hogg M, Runyon MS. Study protocol of a randomised controlled trial of intranasal ketamine compared with intranasal fentanyl for analgesia in children with suspected, isolated extremity fractures in the paediatric emergency department. BMJ Open. 2016 Sep 8;6(9):e012190. doi: 10.1136/bmjopen-2016-012190.
Results Reference
derived

Learn more about this trial

IN Sub-Dissociative Ketamine vs IN Fentanyl

We'll reach out to this number within 24 hrs